28 related articles for article (PubMed ID: 38661611)
1. In vivo CAR T-cell generation in non-human primates using lentiviral vectors displaying a multi-domain fusion ligand.
Nicolai CJ; Parker M; Qin J; Tang W; Ulrich-Lewis JT; Gottschalk R; Cooper S; Hernandez Lopez SA; Parrilla D; Mangio R; Ericson N; Brandes A; Umuhoza S; Michels K; McDonnell M; Park L; Shin S; Leung WH; Scharenberg A; Kiem HP; Larson RP; Beitz L; Ryu B
Blood; 2024 Jun; ():. PubMed ID: 38861668
[TBL] [Abstract][Full Text] [Related]
2. Lentiviral vector determinants of anion-exchange chromatography elution heterogeneity.
Pamenter G; Davies L; Lamont C; Rahim D; Knevelman C; Miskin J; Mitrophanous K; Dikicioglu D; Bracewell DG
Biotechnol Bioeng; 2024 Jun; ():. PubMed ID: 38874319
[TBL] [Abstract][Full Text] [Related]
3. A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells.
Sin WX; Jagannathan NS; Teo DBL; Kairi F; Fong SY; Tan JHL; Sandikin D; Cheung KW; Luah YH; Wu X; Raymond JJ; Lim FLWI; Lee YH; Seng MS; Soh SY; Chen Q; Ram RJ; Tucker-Kellogg L; Birnbaum ME
Nat Biomed Eng; 2024 Jun; ():. PubMed ID: 38834752
[TBL] [Abstract][Full Text] [Related]
4. Long-term stability of clinical-grade lentiviral vectors for cell therapy.
Jadlowsky JK; Leskowitz R; McKenna S; Karar J; Ma Y; Dai A; Plesa G; Chen F; Alexander K; Petrella J; Gong N; Hwang WT; Farrelly O; Barber-Rotenberg J; Christensen S; Gonzalez VE; Chew A; Fraietta JA; June CH
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101186. PubMed ID: 38282894
[TBL] [Abstract][Full Text] [Related]
5. Separation of Activated T Cells Using Multidimensional Double Spiral (MDDS) Inertial Microfluidics for High-Efficiency CAR T Cell Manufacturing.
Jeon H; Perez CR; Kyung T; Birnbaum ME; Han J
Anal Chem; 2024 Jun; ():. PubMed ID: 38889002
[TBL] [Abstract][Full Text] [Related]
6. Quasi-perfusion studies for intensified lentiviral vector production using a continuous stable producer cell line.
Stibbs DJ; Silva Couto P; Takeuchi Y; Rafiq QA; Jackson NB; Rayat ACME
Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101264. PubMed ID: 38827249
[TBL] [Abstract][Full Text] [Related]
7. Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy.
Gutierrez-Guerrero A; Cosset FL; Verhoeyen E
Viruses; 2020 Sep; 12(9):. PubMed ID: 32933033
[TBL] [Abstract][Full Text] [Related]
8. Progress and Perspectives in the Development of Lentiviral Vector Producer Cells.
Ferreira MV; Cabral ET; Coroadinha AS
Biotechnol J; 2021 Jan; 16(1):e2000017. PubMed ID: 32686901
[TBL] [Abstract][Full Text] [Related]
9. Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors.
Chockley P; Patil SL; Gottschalk S
Cytotherapy; 2021 Sep; 23(9):787-792. PubMed ID: 34119434
[TBL] [Abstract][Full Text] [Related]
10. Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors.
Jamali A; Kapitza L; Schaser T; Johnston ICD; Buchholz CJ; Hartmann J
Mol Ther Methods Clin Dev; 2019 Jun; 13():371-379. PubMed ID: 30997367
[TBL] [Abstract][Full Text] [Related]
11. Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD/SCIDγc
Levy C; Fusil F; Amirache F; Costa C; Girard-Gagnepain A; Negre D; Bernadin O; Garaulet G; Rodriguez A; Nair N; Vandendriessche T; Chuah M; Cosset FL; Verhoeyen E
J Thromb Haemost; 2016 Dec; 14(12):2478-2492. PubMed ID: 27685947
[TBL] [Abstract][Full Text] [Related]
12. Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics.
Charitidis FT; Adabi E; Thalheimer FB; Clarke C; Buchholz CJ
Mol Ther Methods Clin Dev; 2021 Dec; 23():359-369. PubMed ID: 34729382
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells.
Cordes N; Kolbe C; Lock D; Holzer T; Althoff D; Schäfer D; Blaeschke F; Kotter B; Karitzky S; Rossig C; Cathomen T; Feuchtinger T; Bürger I; Assenmacher M; Schaser T; Kaiser AD
Mol Ther Methods Clin Dev; 2021 Jun; 21():42-53. PubMed ID: 33768128
[TBL] [Abstract][Full Text] [Related]
14. Optimizing lentiviral vector formulation conditions for efficient ex vivo transduction of primary human T cells in chimeric antigen receptor T-cell manufacturing.
Luostarinen A; Kailaanmäki A; Turkki V; Köylijärvi M; Käyhty P; Leinonen H; Albers-Skirdenko V; Lipponen E; Ylä-Herttuala S; Kaartinen T; Lesch HP; Kekarainen T
Cytotherapy; 2024 Apr; ():. PubMed ID: 38661611
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
